Acknowledgement
The authors wish to thank Ashley Headrick for help in preparing and submitting the commentary article.

Funding
This work was funded by the 10.13039/100000738Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Merit Review Awards 2I01 BX000226 and IMMA-010-19F (AAV), Senior Research Career Scientist Award 1IK6BX004209 (AAV) and the 10.13039/100000060National Institute of Allergy and Infectious Diseases award R44AI122574 (AAV). The contents do not represent the views of the Department of Veterans Affairs or the US Government.

Availability of data and materials
The datasets used and/or analyzed during previous studies are available from the corresponding author on reasonable request.

Author contributions
The commentary article was written, edited and reviewed by AAV, HO and RMR. All authors read and approved the final article.

Competing Interests
Drs. Vandenbark, Offner, Meza-Romero, and OHSU have a significant financial interest in Artielle ImmunoTherapeutics, Inc., a company that may have a commercial interest in the results of this research and technology. This potential conflict of interest has been reviewed and managed by the OHSU and VA Portland Health Care System Conflict of Interest in Research Committees.